← Leaderboards
Assiamira Ferrara
Kaiser Foundation Research Institute
$36,823,631
Attributed
$56,208,157
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.1M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,754,455 · 9
AHRQ$8,453,702 · 1
By mechanism
UH3$22,245,620 · 1
R01$19,745,031 · 5
UG3$9,848,045 · 1
R18$3,690,515 · 1
P30$678,946 · 2
Top collaborators
- Lisa A Croen10 shared
- Susan Denise Brown8 shared
- Monique Marie Hedderson3 shared
- Yeyi Zhu1 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Lisa A Croen$34,075,037
- Lyndsay Ammon Avalos$14,620,948
- Anny H Xiang$8,218,850
- Yeyi Zhu$10,697,351
Others in their field
Top investigators on “Pregnancy”
- Chanza Baytop · Westat, Inc.$271,217,917
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$158,777,707
- Barbara Driver · Westat, Inc.$117,058,181
- Myron S Cohen · Family Health International$101,800,876
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
Research focus
PregnancyWomanGestational DiabetesObesityFutureLife StyleDiabetes MellitusEnrollmentChildPhysical ActivityAffectPreventPostpartum PeriodHigh RiskProgramsNon-Insulin-Dependent Diabetes MellitusReportingCaliforniaInterestGlucoseObesity In ChildrenExposure ToGestational Weight GainDiagnosis
Grant awards (51)
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$2,970,993
UH3 · FY2025 · OD · contact PI
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM$707,911
R01 · FY2025 · DK
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM$44,657
R01 · FY2025 · DK
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,093,705
UG3 · FY2024 · OD · contact PI
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM$696,143
R01 · FY2024 · DK
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM$52,668
R01 · FY2024 · DK
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM - Diversity Supplement$14,840
R01 · FY2024 · DK
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,112,927
UG3 · FY2023 · OD · contact PI
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM$708,598
R01 · FY2023 · DK
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,964,725
UH3 · FY2022 · OD · contact PI
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM$708,632
R01 · FY2022 · DK
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,964,727
UH3 · FY2021 · OD · contact PI
Optimizing a scalable intervention to maximize guideline-recommended diabetes testing after GDM$682,730
R01 · FY2021 · DK
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,964,727
UH3 · FY2020 · OD · contact PI
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$310,572
UH3 · FY2020 · OD · contact PI
HDS CDTR Diabetes and Obesity Prevention Core$68,404
P30 · FY2020 · DK · contact PI
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,709,938
UH3 · FY2019 · OD · contact PI
HDS CDTR Diabetes and Obesity Prevention Core$68,394
P30 · FY2019 · DK · contact PI
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$3,359,938
UH3 · FY2018 · OD · contact PI
HDS CDTR Diabetes and Obesity Prevention Core$68,402
P30 · FY2018 · DK · contact PI
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$2,203,040
UG3 · FY2017 · OD · contact PI
Appropriate Gestational Weight Gain in Overweight/Obese Women$636,325
R01 · FY2017 · HD · contact PI
Prenatal Bisphenol A Exposure and Risk of Gestational Diabetes$571,809
R01 · FY2017 · ES · contact PI
HDS CDTR Diabetes and Obesity Prevention Core$68,411
P30 · FY2017 · DK · contact PI
Early Life Exposure to Endocrine Disrupting Chemicals and Child Growth, Adiposity, and Neurodevelopment$1,438,373
UG3 · FY2016 · OD · contact PI
Appropriate Gestational Weight Gain in Overweight/Obese Women$624,384
R01 · FY2016 · HD · contact PI
Prenatal Bisphenol A Exposure and Risk of Gestational Diabetes$603,913
R01 · FY2016 · ES · contact PI
HDS CDTR Diabetes and Obesity Prevention Core$67,468
P30 · FY2016 · DK · contact PI
Appropriate Gestational Weight Gain in Overweight/Obese Women$659,058
R01 · FY2015 · HD · contact PI
Prenatal Bisphenol A Exposure and Risk of Gestational Diabetes$602,828
R01 · FY2015 · ES · contact PI
Prevention Core$76,007
P30 · FY2015 · DK · contact PI
Appropriate Gestational Weight Gain in Overweight/Obese Women$655,256
R01 · FY2014 · HD · contact PI
Translational Diebetes Prevention in GDM$652,699
R18 · FY2014 · DK · contact PI
Prenatal Bisphenol A Exposure and Risk of Gestational Diabetes$614,462
R01 · FY2014 · ES · contact PI
Prevention Core$76,036
P30 · FY2014 · DK · contact PI
Translational Diebetes Prevention in GDM$622,084
R18 · FY2013 · DK · contact PI
Appropriate Gestational Weight Gain in Overweight/Obese Women$615,274
R01 · FY2013 · HD · contact PI
Prenatal Bisphenol A Exposure and Risk of Gestational Diabetes$610,786
R01 · FY2013 · ES · contact PI
Prevention Core$71,236
P30 · FY2013 · DK · contact PI
Translational Diebetes Prevention in GDM$650,243
R18 · FY2012 · DK · contact PI
Prevention Core$57,294
P30 · FY2012 · DK · contact PI
Translational Diebetes Prevention in GDM$653,861
R18 · FY2011 · DK · contact PI
Prevention Core$57,294
P30 · FY2011 · DK · contact PI
Comparative effectiveness of diabetes prevention strategies in women with GDM$8,453,702
R01 · FY2010 · HS · contact PI
Translational Diebetes Prevention in GDM$649,243
R18 · FY2010 · DK · contact PI
Translational Diabetes Prevention in GDM$227,919
R18 · FY2007 · DK · contact PI
Translational Diabetes Prevention in GDM$234,466
R18 · FY2006 · DK · contact PI
GESTATIONAL DIABETES: DIAGNOSTIC CRITERIA AND OUTCOMES$368,323
R01 · FY2003 · DK
GESTATIONAL DIABETES: DIAGNOSTIC CRITERIA AND OUTCOMES$395,840
R01 · FY2002 · DK
GESTATIONAL DIABETES: DIAGNOSTIC CRITERIA AND OUTCOMES$384,853
R01 · FY2001 · DK
GESTATIONAL DIABETES: DIAGNOSTIC CRITERIA AND OUTCOMES$332,039
R01 · FY2000 · DK